Literature DB >> 9211366

Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients.

S Fishbane1, C Galgano, R C Langley, W Canfield, J K Maesaka.   

Abstract

The assessment of iron status for hemodialysis patients has been hindered by the inaccuracy of commonly used diagnostic tests. A novel assay, the reticulocyte hemoglobin content (CHr), has recently been found to sensitively detect functional iron deficiency among nonuremic patients treated with recombinant erythropoietin (rHuEPO). The purpose of this study was to evaluate the CHr for the assessment of iron status in hemodialysis patients. One hundred sixty-four stable hemodialysis patients had a mean CHr of 27.5 +/- 2.8 pg with a normal distribution of values. The mean CH (mature red cell hemoglobin content) was 26.4 +/- 2.4 pg. There was a close correlation between CHr and CH (r = 0.86, P < 0.0001). A significant subgroup of patients (12.2%) had CHr values < CH. These patients had recent increases in rHuEPO dose, and a lower mean transferrin saturation and hematocrit, suggesting the recent onset of functional iron deficiency due to the increase in rHuEPO dose. In the second phase of the study, 32 patients were randomly selected to receive treatment with a single dose infusion of 1,000 mg of intravenous iron dextran (IVFe). Patients were classified as iron deficient (N = 7) if they responded with a significant reticulocytosis (sustained 1 basis point increase in corrected reticulocyte index within 2 weeks). All other patients were classified as iron replete (N = 25). A CHr < 26 pg at baseline predicted iron deficiency with a sensitivity of 100%, specificity of 80%. The serum ferritin, transferrin saturation and percentage of hypochromic red blood cells all were less accurate. The time to correction of iron deficiency at the level of the reticulocyte was found to be within 48 hours as measured by correction of the mean CHr to > 26 pg, and by the shift of the vast majority of the reticulocyte population to CHr > 26 pg within this time span. We conclude that CHr < 26 pg is an accurate measure of iron status in hemodialysis patients, that a CHr value < CH indicates the acute onset of iron deficiency, and that a single dose infusion of intravenous iron results in correction of iron deficiency at the level of the reticulocyte within 48 hours.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9211366     DOI: 10.1038/ki.1997.323

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  34 in total

Review 1.  Reticulocytes and reticulocyte enumeration.

Authors:  R S Riley; J M Ben-Ezra; R Goel; A Tidwell
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.

Authors:  Adam E Gaweda; Linda J Goldsmith; Michael E Brier; George R Aronoff
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-28       Impact factor: 8.237

3.  Using the hemoglobin content of reticulocytes (RET-He) to evaluate anemia in patients with cancer.

Authors:  Ellinor I B Peerschke; Melissa S Pessin; Peter Maslak
Journal:  Am J Clin Pathol       Date:  2014-10       Impact factor: 2.493

4.  Sodium ferric gluconate complex therapy in anemic children on hemodialysis.

Authors:  Bradley A Warady; R Howard Zobrist; Jingyang Wu; Eileen Finan
Journal:  Pediatr Nephrol       Date:  2005-06-22       Impact factor: 3.714

Review 5.  Iron, anaemia, and inflammatory bowel diseases.

Authors:  C Gasche; M C E Lomer; I Cavill; G Weiss
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

6.  A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.

Authors:  Johann C B Nicholas
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.

Authors:  Kimberly Zumbrennen-Bullough; Jodie L Babitt
Journal:  Nephrol Dial Transplant       Date:  2013-11-13       Impact factor: 5.992

Review 8.  The role of iron supplementation during epoietin treatment for cancer-related anemia.

Authors:  M Hedenus; G Birgegård
Journal:  Med Oncol       Date:  2008-05-13       Impact factor: 3.064

9.  Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells.

Authors:  Wen Guo; Eric Bachman; Michelle Li; Cindy N Roy; Jerzy Blusztajn; Siu Wong; Stephen Y Chan; Carlo Serra; Ravi Jasuja; Thomas G Travison; Martina U Muckenthaler; Elizabeta Nemeth; Shalender Bhasin
Journal:  Aging Cell       Date:  2013-02-28       Impact factor: 9.304

10.  Sideroblastic changes of the bone marrow can be predicted by the erythrogram of peripheral blood.

Authors:  A Rovó; G Stüssi; S Meyer-Monard; G Favre; D Tsakiris; D Heim; J Halter; C Arber; J Passweg; A Gratwohl; A Tichelli
Journal:  Int J Lab Hematol       Date:  2009-08-25       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.